Convolutional Neural Network Can Recognize Drug Resistance of Single Cancer Cells.

Journal: International journal of molecular sciences
Published Date:

Abstract

It is known that single or isolated tumor cells enter cancer patients' circulatory systems. These circulating tumor cells (CTCs) are thought to be an effective tool for diagnosing cancer malignancy. However, handling CTC samples and evaluating CTC sequence analysis results are challenging. Recently, the convolutional neural network (CNN) model, a type of deep learning model, has been increasingly adopted for medical image analyses. However, it is controversial whether cell characteristics can be identified at the single-cell level by using machine learning methods. This study intends to verify whether an AI system could classify the sensitivity of anticancer drugs, based on cell morphology during culture. We constructed a CNN based on the VGG16 model that could predict the efficiency of antitumor drugs at the single-cell level. The machine learning revealed that our model could identify the effects of antitumor drugs with ~0.80 accuracies. Our results show that, in the future, realizing precision medicine to identify effective antitumor drugs for individual patients may be possible by extracting CTCs from blood and performing classification by using an AI system.

Authors

  • Kiminori Yanagisawa
    Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Masayasu Toratani
    Department of Radiation Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Ayumu Asai
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Masamitsu Konno
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Hirohiko Niioka
    Graduate School of Engineering Science, Osaka University, 1-3 Machikane-Yama, Toyonaka, Osaka, 560-8531, Japan.
  • Tsunekazu Mizushima
    Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan.
  • Taroh Satoh
    Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
  • Jun Miyake
    Graduate School of Engineering Science, Osaka University, 1-3 Machikane-Yama, Toyonaka, Osaka, 560-8531, Japan. jun_miyake@bpe.es.osaka-u.ac.jp.
  • Kazuhiko Ogawa
    Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Andrea Vecchione
    Department of Clinical and Molecular Medicine, University of Rome "Sapienza", Santo Andrea Hospital, via di Grottarossa, 1035-00189 Rome, Italy.
  • Yuichiro Doki
    Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan.
  • Hidetoshi Eguchi
    Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Hideshi Ishii
    Department of Disease Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. kogawa@radonc.med.osaka-u.ac.jp hishii@gesurg.med.osaka-u.ac.jp.